ライフサイエンスコーパス: duration of treatment

1 d, how much steroid to give, and the optimum duration of treatment.

2 ay improve overall survival (OS) with longer duration of treatment.

3 t-limiting side effects and a long (48-week) duration of treatment.

4 evel of quantitation (<25 IU/mL) through the duration of treatment.

5 ment should be considered in determining the duration of treatment.

6 e) did not differ between the groups for the duration of treatment.

7 which bisphosphonates should be used and the duration of treatment.

8 dose-dependent but was less with increasing duration of treatment.

9 n deprivation therapy and is correlated with duration of treatment.

10 d youth do not receive adequate follow-up or duration of treatment.

11 and particularly those that can shorten the duration of treatment.

12 ps determine the patient's prognosis and the duration of treatment.

13 and assists in establishing the appropriate duration of treatment.

14 Greater protection was noted with longer duration of treatment.

15 an effect that directly correlated with the duration of treatment.

16 cally depending on the concentration and the duration of treatment.

17 ereas dyskinesias could be best predicted by duration of treatment.

18 r (EE) compared with triglyceride (TG)], and duration of treatment.

19 ivided into years of follow-up or increasing duration of treatment.

20 significantly delayed worm expulsion for the duration of treatment.

21 immediate relapse and higher cost and longer duration of treatment.

22 he intensity of tolerance increases with the duration of treatment.

23 e stage at which embryos were treated or the duration of treatment.

24 eferred over voriconazole, given the lengthy duration of treatment.

25 arding the optimal timing, dosing, route and duration of treatment.

26 hensively investigated and lacks evidence on duration of treatment.

27 with part-time patching and required longer duration of treatment.

28 tudied as a frontline therapy with a defined duration of treatment.

29 6 individuals who received NP throughout the duration of treatment.

30 ons depending on the type of steroid and the duration of treatment.

31 f these differences increased throughout the duration of treatment.

32 o continued intravenous (IV) therapy for the duration of treatment.

33 equirements for amino acid concentration and duration of treatment.

34 troma correlate with the cumulative dose and duration of treatment.

35 establishing a standard recommendation about duration of treatment.

36 n males and possibly in patients with longer duration of treatment.

37 , rendering their eruption tolerable for the duration of treatment.

38 material and with a limited and controllable duration of treatment.

39 the effect depending on the dose of GSPE and duration of treatment.

40 are assessed at diagnosis and throughout the duration of treatment.

41 impacts BMI in adolescents following longer durations of treatment.

42 in the evaluation of the effect of different durations of treatment.

43 o be fixed but increase steadily with longer durations of treatment.

44 r or no prior use of immunosuppressants, and duration of treatment (1 to 24 months vs. 25 to 48 month

45 ome other effects, possibly due to the short duration of treatment (10 months).

46 her was slightly more frequent with a longer duration of treatment: 12 (2.9%) of 416 patients assigne

47 were divided into three groups according to duration of treatment: 24 (N = 14), 48 (N = 82), or 72 (

48 no difference between groups in the average duration of treatment (27.5 [SD 21.5], 24.9 [17.7], 27.9

49 RECENT FINDINGS: Extended duration of treatment (36 months) with adjuvant imatinib

50 assessment and sustainability, (3) type and duration of treatment, (4) initial prognostic factors (m

51 otently inhibits S6K activity throughout the duration of treatment, 4E-BP1 recovers in phosphorylatio

52 d or greater severity increased according to duration of treatment: 90 to 180 days, 1.5 (P=0.23); 181

53 moxifloxacin for isoniazid permits a shorter duration of treatment, a second study was performed in w

54 The duration of treatment after achieving a satisfactory res

55 The optimal duration of treatment after CR is not yet established.

56 of pretreatment before stenting, the optimal duration of treatment after drug-eluting stent implantat

57 se of bromocriptine, long-term outcomes, and duration of treatment after recovery are needed.

58 Despite proven efficacy, the duration of treatment, AIT-associated side effects, and

59 Longer duration of treatment allows restoration of social conne

60 of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertai

61 allocated treatment and received treatment, duration of treatment and cause of discontinuation, main

62 t of SBS, optimal patient selection for use, duration of treatment and cost effectiveness require fur

63 Due to the longer duration of treatment and expensive second-line medicine

64 essed by 2 reviewers, study definitions, and duration of treatment and follow-up.

65 t status, number of treatment interruptions, duration of treatment and interruption, changes in viral

66 trategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or

67 trategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or

68 Median duration of treatment and mean daily dose were 12.5 mont

69 atients in the intervention group had longer duration of treatment and more focus control procedures

70 atients in the intervention group had longer duration of treatment and more focus control procedures

71 ed the association of race and survival with duration of treatment and number of treatment cycles amo

72 The median (range) duration of treatment and number of treatments to achiev

73 vement in PROs that continued throughout the duration of treatment and post-treatment.

74 blingual buprenorphine resulted in a shorter duration of treatment and shorter length of hospital sta

75 If the association we observed between duration of treatment and survival is confirmed, additio

76 aluate the potential association between the duration of treatment and the prevalence of heart valve

77 The optimal duration of treatment and utility of follow-up blood cul

78 Benefit increased with duration of treatment and was consistent across the diff

79 strategy was associated with a shorter total duration of treatment and with no evident safety concern

80 iated with GGTI treatment in vivo limits the duration of treatment and, thus, may limit the therapeut

81 ndent vasodilation in direct relationship to duration of treatments and reduced wall thickness in as

82 , length of stay at the intensive care unit, duration of treatment, and 30-day mortality.

83 Overall survival, duration of treatment, and dose reductions among trial p

84 ient quality of life, can limit the dose and duration of treatment, and may be life-threatening, spec

85 dence of postpartum affective disorder (AD), duration of treatment, and rate of subsequent postpartum

86 outcome measures were risk of postpartum AD, duration of treatment, and recurrence risk.

87 ue to colorectal cancer in relation to dose, duration of treatment, and site of tumour.

88 tly needed for resistant strains, shortening duration of treatment, and targeting different stages of

89 (CEL), little is known about optimal dosing, duration of treatment, and the possibility of cure in th

90 nduction versus maintenance treatment, total duration of treatment, and the utility of therapeutic mo

91 mutations with disease, duration of illness, duration of treatment, and total therapeutic dose of aza

92 initiation of PMPA treatment as well as the duration of treatment are crucial factors for prevention

93 Issues concerning the timing and duration of treatment are discussed.

94 However, the type and duration of treatment are still debated, and the prevent

95 The optimum frequency and duration of treatment are unknown.

96 inimum effective dose and shortest necessary duration of treatment as well as the mechanism of antide

97 of careful risk-benefit review of dosage and duration of treatment as well as their off-label use.

98 Duration of treatment averaged 10.5 +/- 2.6 d.

99 ndent of the underlying risk of relapse, the duration of treatment before randomisation, or the durat

100 trials are required to determine the optimal duration of treatment before widespread use is advocated

101 ultiple logistic regression models confirmed duration of treatment, blasts, and transcript type as in

102 in the number of treatment sessions and the duration of treatment, CBT was more effective in relievi

103 e patients treated with nesiritide, the mean duration of treatment changed minimally, from 2.3 to 2.1

104 and frequency of drug administration, median duration of treatment, clearance and recurrence rates, a

105 tive, are hampered by high pill burden, long duration of treatment, coexistent toxic effects, and an

106 Longer duration of treatment conferred greater fracture risk.

107 In addition to the duration of treatment, core promoter mutation was associ

108 P = 0.001), whereas the cumulative dose and duration of treatment correlate significantly with the d

109 Duration of treatment correlated positively with volumes

110 Duration of treatment, cumulative dose, Orlando stage (s

111 As expected, HDV inhibition exhibited duration-of-treatment dependence.

112 Duration of treatment did not affect relapse in patients

113 conducted on combination antibiotic therapy, duration of treatment, dosing of aminoglycosides, altern

114 cells depend on the viral load, timing, and duration of treatment during the course of the infection

115 The secondary efficacy end point was the duration of treatment effect measured as time from the i

116 t, the mode and frequency of administration, duration of treatment effect, degree of haemostatic prot

117 reatment (QALYs = [gain in utility value] x [duration of treatment effect]).

118 but were limited in evaluating the scope and duration of treatment effects.

119 Mean duration of treatment efficacy was 127 days (SD 37) with

120 but the erosion of the DFS benefit after the duration of treatment ends suggests a potential value fo

121 ration of methadone treatment (adjusted mean duration of treatment episode 466 days [95% CI 450 to 48

122 received ZD9331 daily for 2 weeks, with the duration of treatment escalated to a maximum of 4 weeks,

123 djusted HR, 1.08 [95% CI, 0.59-1.91]) unless duration of treatment exceeded 10 years (6 cases among 3

124 However, shorter durations of treatment failed to increase overall OL den

125 Patient age, previous drug therapy, duration of treatment, flecainide levels and corrected Q

126 e addressed the quality of follow-up care or duration of treatment for depressed youth.

127 esized that clofazimine may also shorten the duration of treatment for drug-susceptible TB.

128 The duration of treatment for established anthrax is controv

129 The optimal dose, time to start, and duration of treatment for many appetite stimulants for c

130 ptimal route of administration, and dose and duration of treatment for mitomycin C.

131 If the duration of treatment for SSI is currently 12 weeks, the

132 The primary end point was the duration of treatment for symptoms of neonatal opioid wi

133 Personalization of the duration of treatment for TB, especially for patients wi

134 The median duration of treatment for the 204 patients was 5.7 month

135 , P<0.0091), and had a significantly shorter duration of treatment for the neonatal abstinence syndro

136 The mean (SD) durations of treatment for the operative and endovascula

137 tion of PMPA treatment, as well as different durations of treatment, for the ability to prevent estab

138 Increasing the duration of treatment from 1 week to 3 weeks resulted in

139 irin allows for the potential to shorten the duration of treatment from 24 to 12-14 weeks without red

140 We varied ligand (dose, chemistry, and duration of treatment), GR (expression level and functio

141 Duration of treatment > 2 years; suppuration and dental

142 Comparing a longer duration of treatment, >6 years vs <=3 years, yielded a

143 nin reuptake inhibitors and who had a longer duration of treatment had significantly lower risks of m

144 Although the optimal duration of treatment has not been determined, more prol

145 concerns over the antibiotics chosen and the duration of treatment have been raised.

146 nt difference in response rates based on the duration of treatment; HCV genotype was the strongest pr

147 The median duration of treatment hiatus was 12 months.

148 efficacy, with potential for shortening the duration of treatment in a majority of patients.

149 uals infected with HCV, as well as a shorter duration of treatment in many individuals.

150 determine the optimal timing, schedule, and duration of treatment in men with bone metastases as wel

151 We evaluated the safety of a shorter duration of treatment in patients with high-risk SAB wit

152 irAE should be considered when deciding the duration of treatment in responding patients.

153 not involved in deciding hospital treatment, duration of treatment in the hospital, and adjustment of

154 As of Jan 5, 2021, the median duration of treatment in the luspatercept group was 153.

155 The mean omega-3 PUFAs dose and duration of treatment in the new trials was 2.4 g/day an

156 rferon alpha-2b and ribavirin dosage for the duration of treatment in the setting of a clinical trial

157 We assessed the impact of PDE-Is on the duration of treatment in tuberculous mice.

158 ource of bias -- mismeasurement of patients' duration of treatment -- in previous research on pharmac

159 Median duration of treatment incorporating overnight wear was 8

160 At data cutoff, median duration of treatment (induction) was 8.9 weeks (IQR 4.1

161 oth the dietary methyl donor content and the duration of treatment influenced methylation and express

162 nt intermissions per 100 study days, and the duration of treatment intermissions per 100 study days.

163 nadotropic hypogonadism after a mean (+/-SD) duration of treatment interruption of 6+/-3 weeks.

164 The risk of chronic GVHD is higher and the duration of treatment is longer after HCT with mobilized

165 or outcome, optimal therapeutic regimens and duration of treatment is much needed.

166 ate antibiotic therapy is important, but the duration of treatment is uncertain.

167 less-in terms of the number of drugs and the duration of treatment-is better.

168 stopped relatively early, and that a longer duration of treatment leads to failure.

169 more of lactic acid bacteria per day for the duration of treatment (median 33 days).

170 iation had a significantly (P < .01) shorter duration of treatment (median, 62.5 days) compared with

171 rug trials as they relate to sample size and duration of treatment necessary to detect an effect from

172 At a median duration of treatment of 16.5 months (range, 0.2 to 39.9

173 ther than disease progression after a median duration of treatment of 24 months, disease recurrence w

174 18% of users reached the minimally required duration of treatment of 3 years (SCIT, 23%; SLIT, 7%).

175 IQR 31-92) after intervention, with a median duration of treatment of 334 days (329-365).

176 days on/10 days off) prednisolone for a mean duration of treatment of 4 years.

177 The duration of treatment of gastrointestinal tuberculosis c

178 a gene relevant to the index drug, a planned duration of treatment of less than 7 consecutive days, a

179 olymerase chain reaction (QPCR) to determine duration of treatment of transplant patients with human

180 The optimal duration of treatment of women with postmenopausal osteo

181 Studying the effect of duration of treatment on prognostic outcomes using real-

182 s the importance of agonist efficacy and the duration of treatment on the neuroprotective effects of

183 ur study were as follows: a relatively short duration of treatment, only three cancer groups included

184 but whether this results from the increased duration of treatment or a higher cumulative dose remain

185 = 3533) infusion for a clinician-determined duration of treatment or until ICU discharge, whichever

186 only), and ability to tolerate full dose and duration of treatment (P < .0001) were predictors of SVR

187 s related to both total dose (P < 0.001) and duration of treatment (P < 0.001).

188 ion in major vascular events with increasing duration of treatment (P<0.001).

189 Duration of treatment, participants receiving dose-spari

190 he degree of suppression correlated with the duration of treatment; patients treated for <1 month had

191 rug, number of dose level reductions, median duration of treatment, percentage of patients who receiv

192 ALCAT yielded valuable information about the duration of treatment periods and the role of placebo re

193 have assessed the appropriate frequency and duration of treatment programs.

194 dose (range across trials: 3.0-12.4 g/d) or duration of treatment (range: 2-12 wk) influenced the re

195 Average duration of treatment ranged from 6 months to 34 months,

196 The duration of treatment ranged from week-long follow up fo

197 wice daily in 28-day cycles for a predefined duration of treatment, ranging from 6 to 26 cycles depen

198 mpared with BR, with no impact on total dose/duration of treatment received.

199 from 24 to 48 or 72 h p.i. or decreasing the duration of treatment reduced effectiveness in preventin

200 of selection of patients, drug regimen, and duration of treatment remain unresolved.

201 direct-acting antiviral drug can reduce the duration of treatment required to achieve sustained vira

202 h problem goal) heavy infection and the mean duration of treatment required to achieve these goals.

203 Median duration of treatment response (using the time to progre

204 However, tumor eradication is rare, and duration of treatment response is limited by the develop

205 nts who received the drug, regardless of the duration of treatment, revealed 14 partial responses (PR

206 Duration of treatment should be further optimized based

207 Technical success, duration of treatment, stroke, return to the operating r

208 curring course of insomnia, both the limited duration of treatments studied and the lack of follow-up

209 However, benefit increased with scheduled duration of treatment, such that allocation to aspirin o

210 Depending on dose and duration of treatment, survival ranged from 57.1% to 80.

211 igible patients with a significantly shorter duration of treatment than with standard-fractionation c

212 irin in the regimen or with extension of the duration of treatment to 12 weeks.

213 or application (time on/time off), and total duration of treatment to attain desired clinical outcome

214 The duration of treatment to stop person-to-person spread of

215 In addition to the duration of treatment, transcript type as well as blasts

216 erapy and irradiation on treatment toxicity, duration of treatment, tumor recurrence, and survival we

217 d point, dosing regimen in the trial, median duration of treatment, tumor type, monthly costs per dru

218 hen 6 mg/kg every 21 days; cohort A) for the duration of treatment (until progression), and after exp

219 nitude of HbA(1c) lowering waned with longer duration of treatment (up to 52 weeks).

220 The mean duration of treatment was 11 days (SD, 4.5), with a 60-d

221 The median duration of treatment was 13.8 months.

222 202 ICU patients with bacteremia, the median duration of treatment was 14 days, but with wide variabi

223 The median duration of treatment was 14 months.

224 The median (range) duration of treatment was 15 (7-34) months; the frequenc

225 Duration of treatment was 18 months.

226 2)] and 40% treated with identical placebo); duration of treatment was 18 months.

227 The mean total duration of treatment was 180 days in the standard-treat

228 The mean duration of treatment was 21 +/- 7 months.

229 The median duration of treatment was 21 months.

230 The mean (+/-SD) duration of treatment was 21.7+/-14.1 months, and the me

231 re recurrent malignancy or death, the median duration of treatment was 23 months.

232 Median duration of treatment was 291 days (IQR 239-354).

233 The median duration of treatment was 3 months (range, 0.25-12.00 mo

234 Duration of treatment was 3 months, followed by repeat e

235 The mean (+/-SD) duration of treatment was 3.5+/-0.9 years in the LHRH-ag

236 e dose was initially 2 mg/kg per day and the duration of treatment was 32 days.

237 The median duration of treatment was 364 days in the risperidone gr

238 mean dosage of aspirin was 273 mg/d and mean duration of treatment was 37 months.

239 Duration of treatment was 4 years.

240 Mean duration of treatment was 4.3 years.

241 Median follow-up was 16.8 months; median duration of treatment was 4.9 months.

242 The median (IQR) duration of treatment was 46.5 (21-92.5) days.

243 The mean duration of treatment was 5.4 years.

244 Median duration of treatment was 6.0 months (IQR 3.7-7.0), 4.6

245 The minimum planned duration of treatment was 60 weeks following randomisati

246 Median duration of treatment was 7.1 months (range 0.7-34.4, IQ

247 The average duration of treatment was 71 to 72 days in each of the t

248 The average duration of treatment was 73 days.

249 The mean duration of treatment was 81 +/- 96 days.

250 The median (IQR) duration of treatment was 9 (7-14) days for neonates wit

251 The median (range) duration of treatment was 9 cycles (1-24), with only 4 p

252 Median duration of treatment was 9 months, with follow-up of 26

253 Median duration of treatment was 9 weeks (IQR 8-14 weeks).

254 Duration of treatment was a median of 90 min (range 25-3

255 the 2 treatment groups was similar when the duration of treatment was considered.

256 Once the maximum-tolerated duration of treatment was determined, the dose of ZD9331

257 Duration of treatment was event-driven and the trial las

258 The duration of treatment was limited to 3 to 16 weeks becau

259 For each medication, the duration of treatment was most often limited by factors

260 Type or duration of treatment was not associated with a second U

261 In those, the median duration of treatment was not reached (95% CI, 24 mo to

262 The median duration of treatment was significantly shorter with bup

263 ower VA at the time of suspension and longer duration of treatment were associated with reduced risk

264 The dose of G-CSF and duration of treatment were correlated with the extent of

265 ian peak viral load, duration of viremia and duration of treatment were highest during primary infect

266 d using reimbursement data; device costs for duration of treatment were provided by sales representat

267 Duration of treatment, which was 20 +/- 2.1 mo in 1980,

268 ould be started and choice of medication and duration of treatment will maximize the benefits of frac

269 The mean duration of treatment with 3% saline was 7.6 days (range

270 findings indicate a modest benefit of longer duration of treatment with AC AHT on vascular dementia a

271 Evidence regarding the appropriate duration of treatment with antibiotic agents in children

272 PSMA SUV(mean), PSMA-avid tumor volume, and duration of treatment with ASI were independently associ

273 Partial responses were observed, but the duration of treatment with AUY922 and erlotinib was limi

274 The appropriate duration of treatment with beta-blocker drugs after a my

275 Median duration of treatment with bevacizumab was 51 weeks (IQR

276 y homogenate of CsA-treated rats relative to duration of treatment with CsA (r2 = 0.486, P < 0.001).

277 hown to significantly accumulate relative to duration of treatment with CsA when immunoreactive bands

278 Shortening the duration of treatment with HCV direct-acting antivirals

279 therapy in some patients, resulting in long duration of treatment with higher doses (>40 mg AD), may

280 luded the duration of untreated disease, the duration of treatment with immunosuppressive medications

281 accelerate drug development and minimize the duration of treatment with ineffective regimens in cance

282 However, the ideal duration of treatment with interferon-free regimens, par

283 An 8-week duration of treatment with LDV/SOF is highly effective i

284 The average duration of treatment with masked trial medication was 1

285 More women engaged in a sufficient duration of treatment with medications compared with psy

286 Median duration of treatment with methotrexate was 21.5 months

287 focal leukoencephalopathy increases with the duration of treatment with natalizumab.

288 italization, number of days in the hospital, duration of treatment with parenteral antibiotics, or nu

289 The duration of treatment with prednisolone at >40 mg on alt

290 treatment), number of deaths on day 30, and duration of treatment with systemic corticosteroids.

291 Median duration of treatment with T-VEC was 13.3 weeks (range,

292 dose of aromatase-inhibitor therapy, and the duration of treatment with tamoxifen).

293 The duration of treatment with thalidomide was too short to

294 The mean +/- SD duration of treatment with the identified atypical antip

295 The appropriate dose of linezolid and duration of treatment with this agent to minimize toxic

296 the onset of inactive disease, or the total duration of treatment with TNFalpha antagonists prior to

297 We aimed to estimate the effect of different durations of treatment with antihypertensive drugs with

298 describe the number of follow-up visits and duration of treatment within 6 months of first prescript

299 ed to recruit 2200 patients, and the minimum duration of treatment would be 6 months.

300 A shorter duration of treatment wth pegylated interferon and ribav